Skip to main content
Ocumension Therapeutics logo

Ocumension Therapeutics — Investor Relations & Filings

Ticker · 1477 ISIN · KYG674111011 LEI · 5493000USURI3SIL4Z85 HKEX Manufacturing
Open in API
Filings indexed 459 across all filing types
Latest filing 2025-01-02 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 1477

About Ocumension Therapeutics

http://www.ocumension.com

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company dedicated to the research, development, and commercialization of first-in-class or best-in-class therapeutics. The company focuses on providing comprehensive treatment solutions for Chinese patients suffering from ocular diseases. Ocumension has established a complete ophthalmic drug product line, currently holding 20 drug assets covering both anterior and posterior segments of the eye. Its portfolio addresses major conditions such as chronic non-infectious uveitis, infective and allergic conjunctivitis, and diabetic macular edema. The company employs a strategy combining continuous scientific innovation, independent R&D, and strategic alliances to sustain the supply of innovative products across the ophthalmology field.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 93% confidence The document is a Hong Kong Stock Exchange Next Day Disclosure Return (Form FF305) detailing changes in issued and treasury shares, including a share repurchase on‐market and reporting of treasury share transactions. This is precisely a report of the company buying back its own shares, matching the definition for Transaction in Own Shares (POS).
2025-01-02 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 97% confidence The document is a Next Day Disclosure Return (FF305) filed under Hong Kong Listing Rules for changes in issued shares and treasury shares, including detailed repurchase transactions and confirmations. It is a statutory disclosure of the company’s own share buybacks and on-market sales of treasury shares, fitting the definition of a Transaction in Own Shares. Therefore, it should be classified as POS.
2024-12-31 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is a regulatory disclosure filed under Hong Kong Exchange rules detailing changes in issued shares, repurchase of treasury shares, and on-market sale of treasury shares. It includes detailed repurchase reports (Section II) and confirmation under Listing Rules, matching the category for company share buybacks and sales of its own shares. Therefore, it is a Transaction in Own Shares filing (Code: POS).
2024-12-30 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 92% confidence The document is a detailed ‘Next Day Disclosure Return’ (Form FF305) required under the Hong Kong Stock Exchange rules, reporting the company’s repurchase of shares (shares held as treasury shares) and changes in issued shares. It provides specifics on the number of shares repurchased, prices, closing balances, and compliance confirmations. This directly corresponds to a report of the company buying back its own shares. Therefore it is classified as a Transaction in Own Shares (POS).
2024-12-27 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 92% confidence The document is the Hong Kong Stock Exchange ‘Next Day Disclosure Return’ (Form FF305) detailing changes in issued shares and treasury shares, specifically reporting a share repurchase of 27,000 shares and confirmations under Main Board/GEM Rules. This is clearly a disclosure of the company’s own share transactions (share buyback). It is not an AGM material, earnings release, or general announcement but the actual regulatory return for share repurchases. This corresponds to ‘Transaction in Own Shares’ (POS).
2024-12-24 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is the Hong Kong Stock Exchange “Next Day Disclosure Return” (Form FF305) reporting changes in issued shares and repurchases/sales of treasury shares under Main Board Rules and GEM Rules. It details on-market buybacks and treasury share movements. This is not an earnings release, management commentary, nor an announcement of a separate report; it is a direct regulatory report of transactions in the company’s own shares. According to our taxonomy, this falls under Transaction in Own Shares (POS).
2024-12-19 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.